These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28627808)

  • 41. Should the patent system for pharmaceuticals be replaced? A theoretical approach.
    Antoñanzas F; Rodríguez-Ibeas R; Juárez-Castelló CA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):617-26. PubMed ID: 24934980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
    Zhang W; Sun H; Guh D; Anis AH
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exploring payments in the US pharmaceutical market from 2011 to 2019: Update on pharmacy benefit manager impact.
    Weinstein EP; Schulman K
    Am Heart J; 2020 Sep; 227():107-110. PubMed ID: 32730906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging roles for pharmacists in performance-based risk-sharing arrangements.
    Calabrese MJ; Cooke CE; Watson K; de Bittner MR
    Am J Health Syst Pharm; 2017 Jul; 74(13):1007-1012. PubMed ID: 28522641
    [No Abstract]   [Full Text] [Related]  

  • 46. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?
    Edlin R; Hall P; Wallner K; McCabe C
    Value Health; 2014 Jun; 17(4):438-44. PubMed ID: 24969005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Subsidy strategy of pharmaceutical e-commerce platform based on two-sided market theory.
    Li C; Huang Z
    PLoS One; 2019; 14(10):e0224369. PubMed ID: 31671133
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pricing and coordination in a dual-channel supply chain with a socially responsible manufacturer.
    Li S; Li M; Zhou N
    PLoS One; 2020; 15(7):e0236099. PubMed ID: 32726323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Toward a conditional price for medicine?].
    Baseilhac E
    Ann Pharm Fr; 2013 Sep; 71(5):330-7. PubMed ID: 24075703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Impact Reimbursement Act on the pharmaceutical market in Poland].
    Giermaziak W
    Pol Merkur Lekarski; 2014 Apr; 36(214):270-3. PubMed ID: 24868902
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Medication prices in Germany--how are they determined?].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
    [No Abstract]   [Full Text] [Related]  

  • 52. Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing.
    Eckermann S; Willan AR
    Pharmacoeconomics; 2013 May; 31(5):393-401. PubMed ID: 23529209
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
    Zhang S; Doucette WR; Urmie JM; Xie Y; Brooks JM
    Res Social Adm Pharm; 2010 Jun; 6(2):121-9. PubMed ID: 20511111
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Italian risk-sharing agreements on drugs: are they worthwhile?
    Garattini L; Curto A; van de Vooren K
    Eur J Health Econ; 2015 Jan; 16(1):1-3. PubMed ID: 24728513
    [No Abstract]   [Full Text] [Related]  

  • 56. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
    Ganslandt M; Maskus KE
    J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan.
    Strohbehn GW; Cooperrider JH; Yang D; Fendrick AM; Ratain MJ; Zaric GS
    Value Health Reg Issues; 2022 Sep; 31():34-38. PubMed ID: 35395499
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk-sharing agreements for innovative drugs: a new solution to old problems?
    de Pouvourville G
    Eur J Health Econ; 2006 Sep; 7(3):155-7. PubMed ID: 16912890
    [No Abstract]   [Full Text] [Related]  

  • 59. The negative impact of rebate contracts on the health care of patients with depression in Germany.
    Kostev K; Fuchs S; Bauer C; May U
    Int J Clin Pharmacol Ther; 2011 Jun; 49(6):397-402. PubMed ID: 21612747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
    Hertzman P; Miller P; Tolley K
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.